Phase 1 Imaging Study of 68Ga-R10602-101 in Hormone Receptor-Positive Breast Cancer
Radionetics Oncology
Summary
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Description
There are three eligible disease populations for the study. Population 1 are patients with metastatic or locoregionally recurrent, endocrine-resistant, ER+ and/or PR+ breast cancer who have received at least one line of chemotherapy or ADC. Population 2 are patients with ER+ and HER2- locoregional or metastatic non-resectable breast adenocarcinoma with progression on at least one line of prior endocrine therapy in the adjuvant or metastatic setting and starting next line of therapy that will include tamoxifen, fulvestrant, aromatase inhibitor, or elacestrant with or without ovarian suppression…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Breast Cancer Eligibility: * Population 1: Pathologically confirmed ER and/or PR positive, locoregionally recurrent or metastatic breast cancer that is refractory to endocrine therapy (progression on at least one line of endocrine therapy and determined by the investigator that Study Participant would not benefit from additional endocrine therapy) who have received at least one line of chemotherapy or antibody drug conjugate in the metastatic setting (recurrence within 6 months of adjuvant chemotherapy counts as one line of therapy). There is no limit on prior numbe…
Interventions
- Drug68Ga-R10602 injection
68Ga-R10602 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions in hormone receptor positive breast cancer
Locations (6)
- UCLA Department of Medicine - Hematology/OncologyLos Angeles, California
- Indiana University Melvin and Bren Simon Cancer CenterIndianapolis, Indiana
- University of IowaIowa City, Iowa
- University of Michigan MedicineAnn Arbor, Michigan
- MD Anderson Cancer CenterHouston, Texas
- University of Utah, Huntsman Cancer InstituteSalt Lake City, Utah